鈉-葡萄糖共轉運蛋白2(SGLT2)抑制劑是一類新興的治療糖尿病的藥物.近年來,遺傳學和藥理學研究發(fā)現,胃腸道SGLT1蛋白也可能成為一個有治療前景的藥物靶點.SGLT1/SGLT2雙靶點抑制劑的開發(fā)將為糖尿病的治療提供另一個非胰島素依賴的途徑.臨床研究表明,sotagliflozin可以通過雙重抑制SGLT1和SGLT2的作用來降低餐后血糖、升高GLP-1和促進尿糖排出.因此,這些特征使得sotagliflozin在對1型和2型糖尿病的治療方面具有重要臨床意義.

The sodium-dependent glucose transporter 2 (SGLT2) inhibitors is an important emerging class for the treatment of diabetes. In recent years, genetic and pharmacology researches have indicated that gastrointestinal SGLT1 inhibitors may also be an appropriate therapeutic target to treat diabetes. Combining SGLT1 and SGLT2 inhibitors in a single molecule would provide complementary insulin-independent mechanisms to treat diabetes. Therefore, sotagliflozin has been developed as a dual inhibitor of SGLT1 and SGLT2. The differentiating clinical features of dual inhibitor of SGLT1 and SGLT2 include a large postprandial glucose reduction, elevation of glucagon-like peptide 1 and modest urinary glucose excretion. These features may have clinical implications for the use of sotagliflozin in the treatment of both type 1 and type 2 diabetes.

天津市應用基礎與前沿技術研究計劃項目(14JCZDJC33500)